Advertisement

Biological Trace Element Research

, Volume 56, Issue 1, pp 117–124 | Cite as

Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong

  • Shu Yu Yu
  • Ya Jun Zhu
  • Wen Gang Li
Article

Abstract

High rates of hepatitis B virus (HBV) infection and primary liver cancer (PLC) are present in Qidong county. Epidemiological surveys demonstrated an inverse association between selenium (Se) level and regional cancer incidence, as well as HBV infection. Four-year animal studies showed that dietary supplement of Se reduced the HBV infection by 77.2% and liver precancerous lesion by 75.8% of ducks, caused by exposure to natural environmental etiologic factors. An intervention trial was undertaken among the general population of 130,471. Individuals in five townships were involved for observation of the preventive effect of Se. The 8-yr follow-up data showed reduced PLC incidence by 35.1% in selenized table salt supplemented vs the nonsupplemented population. On withdrawal of Se from the treated group, PLC incidence rate began to increase. However, the inhibitory response to HBV was sustained during the 3-yr cessation of treatment. The clinical study among 226 Hepatitis B Surface Antigen (HBsAg)-positive persons provided either 200 μg of Se in the form of selenized yeast tablet or an identical placebo of yeast tablet daily for 4 yr showed that 7 of 113 subjects were diagnosed as having PLC in the placebo group, whereas no incidence of PLC was found in 113 subjects supplemented with Se. Again on cessation of treatment, PLC developed at a rate comparable to that in the control group, demonstrating that a continuous intake of Se is essential to sustain the chemopreventive effect.

Index Entries

Selenium Hepatitis Primary liver cancer Chemoprevention Human 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    R. P. Beasley and C. C. Lin, Hepatoma risk among HBsAg carriers,Am. J. Epidemiol. 108, 247 (1978).Google Scholar
  2. 2.
    W. G. Li, and L. Q. Shao, Experimental study on selenic blockage of primary hepatocarcinoma induced by aflatoxin B1 in rats.Chinese J. Prevent. Med. 21, 11–12 (1987).Google Scholar
  3. 3.
    S. Y. Yu, Y. J. Zhu, and W. G. Li, Selenium chemoprevention of liver cancer in animals and possible human application,Biol. Trace Element Res. 15, 231–241 (1988).CrossRefGoogle Scholar
  4. 4.
    J. E. Spallholz, Selenium: What role in immunity and immune cytotoxcity, in:Selenium in Biology and Medicine, J. E. Spallholz, J. L. Martin, and H. E. Ganther, eds., Westport, CT, pp. 103–117 (1981).Google Scholar
  5. 5.
    J. E. Spallholz, Anti-inflammatory, Immunologic and Carcinostatic Attributes of Selenium in Experimental Animals, in:Diet and Resistance of Disease, M. Phillips and A. Beetz, eds., Plenum, New York, pp. 43–62, (1981).Google Scholar
  6. 6.
    L. D. Koller, J. H. Exon, P. A. Talcott, C. A. Osborne, and G. M. Henningsen, Immune response in rats supplemented with selenium.Clin. Exp. Immunol. 63, 570–576 (1986).PubMedGoogle Scholar
  7. 7.
    S. Y. Yu, P. Ao, L. M. Wang, S. L. Huang, H. C. Chen, X. P. Lu, and Q. Y. Liu, Biochemical and cellular aspects of the anticancer activity of selenium.Biol. Trace Element Res. 15, 243–255 (1988).Google Scholar
  8. 8.
    S. Y. Yu, X. P. Lu, and S. D. Liao, The regulatory effect of selenium on the expression of oncogenes associated with proliferation and differentiation on tumor cells, in:Metal Ions in Biology and Medicine, P. H. Collory, L. A. Poirier, M. Manfait, and J. C. Etienne, eds., Libbey Eurotext, Paris, pp. 487–489 (1990).Google Scholar

Copyright information

© Humana Press Inc. 1997

Authors and Affiliations

  • Shu Yu Yu
    • 1
  • Ya Jun Zhu
    • 1
  • Wen Gang Li
    • 2
  1. 1.Cancer Institute, Chinese Academy of Medical SciencesPeking Union Medical CollegeBeijingP.R. China
  2. 2.Qidong Liver Cancer InstituteJiangsuP.R. China

Personalised recommendations